Compare BLZE & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLZE | IMRX |
|---|---|---|
| Founded | 2007 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 273.4M | 232.9M |
| IPO Year | 2021 | 2021 |
| Metric | BLZE | IMRX |
|---|---|---|
| Price | $4.99 | $6.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $9.50 | ★ $17.20 |
| AVG Volume (30 Days) | 884.2K | ★ 1.1M |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $141,859,000.00 | N/A |
| Revenue This Year | $16.43 | N/A |
| Revenue Next Year | $11.20 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 15.73 | N/A |
| 52 Week Low | $3.94 | $1.10 |
| 52 Week High | $10.86 | $10.08 |
| Indicator | BLZE | IMRX |
|---|---|---|
| Relative Strength Index (RSI) | 33.89 | 43.00 |
| Support Level | $4.50 | $6.42 |
| Resistance Level | $4.78 | $6.81 |
| Average True Range (ATR) | 0.26 | 0.47 |
| MACD | 0.18 | -0.10 |
| Stochastic Oscillator | 97.65 | 9.07 |
Backblaze Inc provides cloud storage services. The company offers services such as Backblaze B2 Cloud Storage, which enables customers to store data, developers to build applications, and partners to expand their use cases. It is offered as a consumption-based Infrastructure-as-a-Service (IaaS) and serves use cases including backups, multi-cloud, application development, and ransomware protection and Backblaze Computer Backup automatically backs up data from laptops and desktops for businesses and individuals. Geographically, it derives a majority of revenue from the United States and the rest from the United Kingdom, Canada, and Other regions.
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.